THURSDAY, APRIL 2nd | 1:30PM EST
Biomarkers can move a program forward fast.
Or slow it down with rework.
Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use, assay design and platform choice so your biomarker data supports real decisions.
REGISTER NOW
Click Here to Register Now for the Biomarkers Roundtable
Learning Objectives:
- How to define context of use so your biomarker strategy holds up as studies scale
- When a ligand binding assay (LBA) makes sense vs a molecular approach
- How to choose quantitative polymerase chain reaction (qPCR) vs droplet digital polymerase chain reaction (ddPCR) based on sensitivity and range needs
- What to consider for multiplexing without generating data you cannot act on
- How matrix choice changes the plan, including plasma, tissue and cerebrospinal fluid (CSF)
- What “fit for purpose” can look like across early research, preclinical and clinical stages
About the Expert Speakers:
- Dr. Dominic Warrino, PhD – Senior Director of Scientific Services at KCAS Bio: Dominic leads a team of scientific advisors for both clients and internal teams for development, validation, and sample analysis for support of PK, immunogenicity, and biomarker methods for a wide range of therapeutics. Dominic has 30 years of experience developing and validating assays for support of drug development.
- Carrie Vyhlidal, PhD – Associate Director, BioPharma Sciences – Molecular at KCAS Bio: Carrie leads molecular assay development using platforms such as qPCR, and ddPCR. With more than 20 years of experience in genetic and genomic assay design for DNA and RNA biomarkers, she brings deep expertise in advancing biomarker science.
- Lindsay Rutherford, PhD – Senior Scientific Advisor at KCAS Bio: Lindsay specializes in Ligand Binding Assay (LBA) services. With more than 15 years of experience in assay development, she previously led the Large Molecule Method Development team at ICON. Prior to working in the CRO space, she spent a decade in diagnostics specializing in biomarker discovery and development. Her expertise spans the full spectrum of biomarkers and bioanalytical assay design.